Literature DB >> 19327775

Aldosterone blockade by Spironolactone improves the hypertensive vascular hypertrophy and remodeling in angiotensin II overproducing transgenic mice.

Sachiko Sakurabayashi-Kitade1, Yoshikazu Aoka, Hirotaka Nagashima, Hiroshi Kasanuki, Nobuhisa Hagiwara, Masatoshi Kawana.   

Abstract

OBJECTIVES AND
BACKGROUND: Recent evidence has revealed that aldosterone (ALDO) is produced in the vasculature, and acts directly in the cardiovascular system. This study was designed to examine the role of ALDO in the process of long-term renin-angiotensin system (RAS) induced vascular remodeling. MATERIAL AND
METHOD: Hypertensive transgenic mice that overproduce angiotensin II (AngII), i.e., Tsukuba-Hypertensive-Mice (THM), were given tap water or 1% salt water and treated with or without Spironolactone (SPRL: 20mg/kg/day) for 4 weeks. We also employed A7r5 cells and investigated the effect of SPRL on the AngII mediated signal transduction in the vascular smooth muscle cells.
RESULTS: Intimal hyperplasia, medial hypertrophy and degradation of medial elastic laminae were observed in the abdominal aorta, independent of blood pressure. Taking 1% salt water markedly enhanced these changes. In contrast, SPRL-treated THM showed almost complete disappearance of these intimal hyperplasia and medial hypertrophy. Osteopontin (OPN) was markedly up-regulated in the intima and media. However, it was inhibited by SPRL treatment in spite of high level of AngII. In A7r5 cells, AngII (10(-7)muM) induced OPN expression and pretreatment with MEK, PI3K, and EGFR inhibitor suppressed it. SPRL pretreatment also inhibited AngII-induced ERK and AKT phosphorylation, and resulted in the suppression of AngII-induced OPN expression.
CONCLUSIONS: ALDO blockade by SPRL restores the vascular remodeling caused by the long-term RAS enhancement even in the high level of AngII, independent of blood pressure. Blocking AngII alone may not be sufficient, and direct ALDO blockade is also important to prevent vascular disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19327775     DOI: 10.1016/j.atherosclerosis.2009.01.039

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  18 in total

1.  Angiotensin II- and salt-induced kidney injury through Rac1-mediated mineralocorticoid receptor activation.

Authors:  Wakako Kawarazaki; Miki Nagase; Shigetaka Yoshida; Maki Takeuchi; Kenichi Ishizawa; Nobuhiro Ayuzawa; Kohei Ueda; Toshiro Fujita
Journal:  J Am Soc Nephrol       Date:  2012-03-22       Impact factor: 10.121

2.  A randomized, double-blind, placebo-controlled trial of spironolactone on carotid intima-media thickness in nondiabetic hemodialysis patients.

Authors:  Antonio Vukusich; Sonia Kunstmann; Cristian Varela; Daniela Gainza; Sebastian Bravo; Daniela Sepulveda; Gabriel Cavada; Luis Michea; Elisa T Marusic
Journal:  Clin J Am Soc Nephrol       Date:  2010-06-03       Impact factor: 8.237

3.  Diuretics prevent Rho-kinase activation and expression of profibrotic/oxidative genes in the hypertensive aortic wall.

Authors:  Patricio Araos; David Mondaca; Jorge E Jalil; Cristián Yañez; Ulises Novoa; Italo Mora; María Paz Ocaranza
Journal:  Ther Adv Cardiovasc Dis       Date:  2016-09-01

4.  An angiotensin II- and NF-kappaB-dependent mechanism increases connexin 43 in murine arteries targeted by renin-dependent hypertension.

Authors:  Florian Alonso; Nathalie Krattinger; Lucia Mazzolai; Alexander Simon; Gérard Waeber; Paolo Meda; Jacques-Antoine Haefliger
Journal:  Cardiovasc Res       Date:  2010-01-28       Impact factor: 10.787

5.  Central interactions of aldosterone and angiotensin II in aldosterone- and angiotensin II-induced hypertension.

Authors:  Baojian Xue; Terry G Beltz; Yang Yu; Fang Guo; Celso E Gomez-Sanchez; Meredith Hay; Alan Kim Johnson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2010-11-26       Impact factor: 4.733

6.  Aldosterone enhances IGF-I-mediated signaling and biological function in vascular smooth muscle cells.

Authors:  Teresa Cascella; Yashwanth Radhakrishnan; Laura A Maile; Walker H Busby; Katherine Gollahon; Annamaria Colao; David R Clemmons
Journal:  Endocrinology       Date:  2010-09-29       Impact factor: 4.736

Review 7.  Vascular endothelial function and hypertension: insights and directions.

Authors:  Kodlipet Dharmashankar; Michael E Widlansky
Journal:  Curr Hypertens Rep       Date:  2010-12       Impact factor: 5.369

8.  Tempol, a superoxide dismutase mimetic, prevents cerebral vessel remodeling in hypertensive rats.

Authors:  Paulo Wagner Pires; Christian Deutsch; Jonathon Lee McClain; Curt Thomas Rogers; Anne McLaren Dorrance
Journal:  Microvasc Res       Date:  2010-06-22       Impact factor: 3.514

9.  Mineralocorticoid receptor antagonism attenuates experimental pulmonary hypertension.

Authors:  Ioana R Preston; Kristen D Sagliani; Rod R Warburton; Nicholas S Hill; Barry L Fanburg; Iris Z Jaffe
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-03-01       Impact factor: 5.464

10.  Impact of mineralocorticoid receptor blockade with direct renin inhibition in angiotensin II-dependent hypertensive mice.

Authors:  Atsushi Hashimoto; Yoshimichi Takeda; Shigehiro Karashima; Mitsuhiro Kometani; Daisuke Aono; Masashi Demura; Takuya Higashitani; Seigo Konishi; Takashi Yoneda; Yoshiyu Takeda
Journal:  Hypertens Res       Date:  2020-05-12       Impact factor: 3.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.